Archive Notice - OSHA Archive

NOTICE: This is an OSHA Archive Document, and may no longer represent OSHA Policy. It is presented here as historical content, for research and review purposes only.

OSHA requirements are set by statute, standards and regulations. Our interpretation letters explain these requirements and how they apply to particular circumstances, but they cannot create additional employer obligations. This letter constitutes OSHA's interpretation of the requirements discussed. Note that our enforcement guidance may be affected by changes to OSHA rules. Also, from time to time we update our guidance in response to new information. To keep apprised of such developments, you can consult OSHA's website at https://www.osha.gov.

June 29, 1993

Ms. Jill Haukos
Associate Director for
Special Projects
Texas Tech University
Health Sciences Center
School of Medicine - Department of
Preventive Medicine
NPTN-Antimicrobial Complaint System
Lubbock, Texas 79430

Dear Ms. Haukos:

This is in response to your letter of April 5 regarding the Occupational Safety and Health Administration (OSHA) regulation 29 CFR 1910.1030, "Occupational Exposure to Bloodborne Pathogens." Specifically, you requested confirmation of information received during a telephone conversation you had with a member of my staff.

The information you received was as follows, according to your correspondence:

1. OSHA Instruction CPL 2-2.44C is still the current version. Proposed revisions have not been approved and published yet.

2. OSHA assumes that a product labeled for TB will be effective against HIV-1 and, therefore, HIV-1 label claims are not needed for compliance with the bloodborne pathogens regulation. Questions on this topic should be routed to the Regional Bloodborne Pathogen Coordinator with the regional OSHA offices.

3. OSHA will accept an HIV-1 label claim for products being used in HIV-1 research laboratories where that is the only pathogen that could be found in the samples (blood or tissue culture, etc...). If there is any chance of HBV, the lab will need a TB effective product.

All of these statements are correct, however we would like to add to item #3. If there is any chance of not only HBV presence, but presence of any bloodborne pathogen other than HIV, the lab will need a tuberculocidal disinfectant.

We hope this information is responsive to your concerns. Thank you for your interest in employee safety and health.

Sincerely,



Roger A. Clark, Director
Directorate of Compliance Programs




April 5, 1993

Laura Lewis
Office of Compliance Programs
Occupational Safety
and Health Administration
Washington, D.C. 20210

Dear Ms. Lewis:

Thank you for assisting our organization in understanding OSHA's stance on antimicrobial products for compliance with the Occupational Safety and Health Administration (OSHA) regulation 29 CFR 1910.1030, "Occupational Exposure to Bloodborne Pathogens". In order to communicate this information to our callers, we need verification that we have interpreted it correctly. Therefore, we would appreciate your review of the information below:

1. OSHA Instruction CPL 2-2.44C is still the current version. Proposed revisions have not been approved and published yet.

2. OSHA assumes that a product labeled for TB will be effective against HIV-1 and, therefore, HIV-1 label claims are not needed for compliance with the bloodborne pathogen regulation. Questions on this topic should be routed to the Regional Bloodborne Pathogen Coordinator with the regional OSHA offices.

3. OSHA will accept an HIV-1 label claim for products being used in HIV-1 research laboratories where that is the only pathogen that could be found in the samples (blood or tissue culture, etc...). If there is any chance of HBV they will need a TB effective product.

Please indicate that you agree with these statements by signing the signature block below:

___________________________________         ______________________
Laura Lewis, Compliance Office OSHA         Date

If we do not receive this letter back, or hear from you regarding changes by April 19, 1993, we will assume that you agree with these points and will communicate this information to our callers. Thank you for your time and assistance.

Sincerely,



Jill F. Haukos
Associate Director
for Special Projects